白蛋白结合型紫杉醇联合卡铂治疗晚期三阴性乳腺癌的疗效评估

摘要
图/表
参考文献
相关文章 (7)

全文: PDF (1238 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨白蛋白结合型紫杉醇联合卡铂治疗晚期三阴性乳腺癌(TNBC)的近期和远期疗效。方法选取2018-03-01至2020-12-31解放军总医院第三医学中心肿瘤科收治的120例晚期转移性TNBC为研究对象,按随机数字表法平均分为两组,对照组采用白蛋白结合型紫杉醇联合吉西他滨方案治疗,观察组采用白蛋白结合型紫杉醇联合卡铂方案治疗,对比观察两组患者的近期治疗效果、血清肿瘤指标变化、远期治疗效果及不良反应发生情况。结果在随访近期,两组患者的客观缓解率(objective response rate, ORR)及疾病控制率(disease control rate, DCR)对比差异无统计学意义,观察组患者的血清CA125、CA15-3、中期因子(MK)及血小板第4因子(PF4)水平均显著低于对照组(P<0.05),观察组中位无进展生存时间(mPFS)明显长于对照组(4.20个月 vs. 3.44个月,P<0.05),两组患者的中位总生存时间(mOS)对比差异无统计学意义;在随访远期,观察组的mPFS明显优于对照组(6.77个月 vs. 5.75个月,P<0.05),观察组患者的mOS明显优于对照组(10.77个月 vs. 8.78个月,P<0.05)。两组患者的治疗不良反应发生率对比无统计学差异。结论白蛋白结合型紫杉醇联合卡铂的近期、远期治疗效果均优于白蛋白结合型紫杉醇联合吉西他滨,而两种方案的不良反应未见明显差异。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	何波
	侯晓杰
	慕媛

关键词 ：晚期三阴性乳腺癌, 白蛋白结合型紫杉醇, 卡铂, 吉西他滨

Abstract：Objective To observe the short and long term efficacy of albumin-bound paclitaxel combined with carboplatin in the treatment of advanced triple-negative breast cancer(TNBC).Methods A total of 120 patients with advanced metastatic TNBC admitted to the Oncology Department of the Third Medical Center of Chinese PLA General Hospital from March 1, 2018 to December 31, 2020 were selected as the research objects. They were divided into two groups according to the method of random number. The control group was treated with albumin-bound paclitaxel combined with gemcitabine regimen, while the observation group was treated with albumin-bound paclitaxel combined with carboplatin regimen. The short-term treatment effect, changes of serum tumor indexes, long-term treatment effect and incidence of adverse reactions were compared between the two groups.Results During the short-term follow-up, there was no significant difference in Objective response rate (ORR)and disease control rate (DCR) between the two groups (P<0.05). Serum CA125, CA15-3, MK and PF4 in the observation group were significantly lower than those in the control group, and the median progression-free survival time (mPFS) in the observation group was significantly longer than that in the control group (4.20 months vs. 3.44 months, P<0.05), there was no significant difference in mOS between the two groups. In the long-term follow-up, mPFS of the observation group was significantly better than that of the control group (6.77 months vs. 5.75 months, P<0.05), and mOS of the observation group was significantly better than that of the control group (10.77 months vs. 8.78 months, P<0.05). There was no significant difference in adverse reactions between the two groups.Conclusions The short-term and long-term efficacy of albumin-bound paclitaxel combined with carboplatin is due to the combination of albumin-bound paclitaxel and gemcitabine, and there is no significant difference in adverse reactions between the two kinds of treatment.

Key words： advanced triple-negative breast cancer albumin-bound paclitaxel carboplatin gemcitabine

收稿日期: 2022-09-19

ZTFLH:

R737.9

通讯作者: 慕媛,E-mail: 263364389@qq.com

作者简介: 何波,硕士,主治医师。

引用本文:

何波, 侯晓杰, 慕媛. 白蛋白结合型紫杉醇联合卡铂治疗晚期三阴性乳腺癌的疗效评估[J]. 武警医学, 2023, 34(2): 150-156. HE Bo, HOU Xaojie, MU Yuan. Evaluation of the efficacy of albumin-bound paclitaxel combined with carboplatin in treatment of advanced triple-negative breast cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(2): 150-156.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2023/V34/I2/150

[1]	Yin L, Duan J J, Bian X W, et al. Triple-negative breast cancer molecular subtyping and treatment progress [J]. Breast Cancer Res, 2020, 22(1): 61.
[2]	Milioli H H, Tishchenko I, Riveros C, et al Basal-like breast cancer: molecular profiles, clinical features and survival outcomes[J]. BMC Med Genomics, 2017,10(1):19.
[3]	Bergin A R T, Loi S. Triple-negative breast cancer: recent treatment advances[J]. F1000Res, 2019,8:F1000 Faculty Rev-1342.
[4]	Kim R, An M, Lee H, et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer [J]. Cancer Discov, 2022, 12(4): 984-1001.
[5]	Hu X C, Zhang J, Xu B H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Oncol, 2015, 16(4): 436-446.
[6]	Zhang J, Lin Y, Sun X J, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer [J]. Ann Oncol, 2018, 29(8): 1741-1747.
[7]	Kundranda M N, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions[J]. Drug Des Devel Ther, 2015, 9: 3767-3777.
[8]	Forero-Torres A, Varley K E, Abramson V G, et al. TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer [J]. Clin Cancer Res, 2015, 21(12): 2722-2729.
[9]	Blohmer J U, Link T, Reinsch M, et al. Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: the geparX 2×2 randomized clinical trial [J]. JAMA Oncol, 2022, 8(7): 1010-1018.
[10]	冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]. 北京: 第三届中国肿瘤内科大会, 2009.
[11]	Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools [J]. Eur J Cancer, 2010, 46(3): 479-494.
[12]	Garrida-Castro A C, Lin N U, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment [J]. Cancer Disc, 2019, 9(2): 176-198.
[13]	Parisi A, Palluzzi E, Cortellini A, et al. First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience [J]. Clin Transl Oncol, 2020, 22(1): 158-162.
[14]	梁旭, 李惠平, 邸立军, 等. 白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析 [J]. 中国癌症杂志, 2014, 24(11): 836-845.
[15]	Yardley D A, Coleman R, Conte P, et al. Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial [J]. Ann Oncol, 2018, 29(8): 1763-1770.
[16]	桑蝶, 张频, 李青, 等. 白蛋白结合型紫杉醇治疗多线化疗失败乳腺癌的疗效及安全性分析 [J]. 临床药物治疗杂志, 2018, 16(7): 28-33.
[17]	Tutt A, Tobey H, Cheang M C U, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial [J]. Nat Med, 2018, 24(5): 628-637.
[18]	陈玉丽, 朱勤伟, 隋晓梅, 等. BRD4沉默联合吉西他滨为治疗三阴性乳腺癌提供新的治疗方案 [J]. 中国癌症杂志, 2016, 26(9): 750-755.
[19]	乔红梅, 陈亮, 丁富强. CEA、CA125、CA15-3在吉西他滨治疗乳腺癌化疗前后的表达及意义 [J]. 癌症进展, 2017, 15(8): 926-928.
[20]	Filippou P S, Karagiannis G S, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target [J]. Oncogene, 2020, 39(10): 2040-2054.
[21]	Vandercappellen J, van Damme J, Struye S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer [J]. Cytokine Growth Factor Rev, 2011, 22(1): 1-18.